Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 13|pp 17548—17567

Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer

Xi Yang1, Yuanfeng Wei1, Feng Sheng2, Yirong Xu3, Jiao Liu3, Ling Gao1, Ju Yang4, Xinchen Sun5, Junxing Huang3, Qing Guo3
  • 1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
  • 2Department of Neurosurgery, Taizhou People’s Hospital, Taizhou, China
  • 3Department of Oncology, Taizhou People’s Hospital, Taizhou, China
  • 4Department of Pathophysiology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, China
  • 5Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
* Equal contribution
Received: November 16, 2020Accepted: June 14, 2021Published: July 7, 2021
https://doi.org/10.18632/aging.203245

Copyright: © 2021 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The C-X-C motif (CXC) chemokines are a family of chemotactic molecules that have been identified as potential prognostic markers and prospective therapeutic targets for many kinds of cancer types. Increasing evidence shows that CXC chemokines are associated with the progression of colorectal cancer (CRC); however, the correlations of CXC chemokines with prognostic and immune infiltrates in CRC remain to be clarified. In this study, we analyzed the mRNA expression level, prognostic data and immune infiltrates of CXC chemokines in CRC patients from the Gene Expression Profiling Interactive Analysis, Oncomine, cBioPortal and databases using GeneMANIA, STRING, DAVID 6.8, and TIMER. Our results showed that CXCL1/2/3/4/5/8/9/10/11/13/14/16 were significantly overexpressed in CRC tissues. Furthermore, expression of CXCL1/2/3/9/10/11 was associated with tumor stage in CRC. A significant association was also identified between the co-expression of CXCL16 with EGFR, KRAS and NRAS. In addition, the survival analysis suggested that high CXCL2/3/8/9/10/11/14 expression is correlated with clinical outcomes of CRC patients. Moreover, a significant association was observed between the CXCL8/9/10/11 expression and immune infiltration in colonic and rectal adenocarcinoma. Overall, CXC chemokines are not only implicated as prognostic biomarkers for CRC patients, but may also influence the immune status of CRC tissues.